Generated: May 28, 2017
|Title:||Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole|
|Abstract:||A method for treatment of gastric acid related diseases by inhibition of gastric acid secretion comprising administering to a mammal in need of treatment a therapeutically effective amount of the (-)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benz imidazole or a pharmaceutically acceptable salt thereof, so as to effect decreased interindividual variation in plasma levels upon administration. The use of the (-)-enantiomer of omeprazole to receive increased average plasma levels (AUC) upon administration of the same doses of the (-)-enantiomer of omeprazole compared to those of racemic omeprazole is also claimed, as well as an improved antisecretory effect and a better clinical effect.|
|Inventor(s):||Lindberg; Per (Molndal, SE), Weidolf; Lars (Vastra Frolunda, SE)|
|Assignee:||Astra Aktiebolag (Sodertalje, SE)|
Patent Claim Types:|
see list of patent claims
|Use; Dosage form; Delivery; Composition;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Hong Kong||1028044||► Subscribe|
|Hong Kong||1028045||► Subscribe|
|European Patent Office||1020461||► Subscribe||C300482||Netherlands||► Subscribe|
|European Patent Office||1020461||► Subscribe||91870||Luxembourg||► Subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.